Bernstein Initiates Coverage On Bristol-Myers Squibb with Market Perform Rating, Announces Price Target of $56
Portfolio Pulse from Benzinga Newsdesk
Bernstein has initiated coverage on Bristol-Myers Squibb (NYSE:BMY) with a Market Perform rating and set a price target of $56.
October 17, 2024 | 4:34 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Bernstein has initiated coverage on Bristol-Myers Squibb with a Market Perform rating and a price target of $56, indicating a neutral outlook.
The Market Perform rating suggests that Bernstein expects BMY to perform in line with the market. The price target of $56 provides a specific valuation expectation, which is crucial for investors. However, the neutral rating implies no significant short-term price movement is expected.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100